The Influence of Caffeine Supplementation on Specific Performance and Training Activities
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03822663 |
Recruitment Status :
Suspended
(Pandemic caused by Coronavirus.)
First Posted : January 30, 2019
Last Update Posted : April 10, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Supplementation Sports | Dietary Supplement: Caffeine supplementation Dietary Supplement: Placebo treatment | Phase 3 |
Caffeine (CAF) is often proposed as an ergogenic agent, especially during high-intensity efforts. CAF supplementation may reduce effort-induced multi-faceted symptoms of fatigue and can improve psychomotor functions (like agility or decision-making processes), which is required during the intermittent high-intensity efforts in combat sports and speed-strength disciplines. Moreover, it is suggested that CAF treatment is associated with increased glycolytic activity during simulated or real training/competition bouts, which results in performance and physical capacity improvement.
However, there are hardly any data on the individual CAF-induced and dose-dependent changes in physical capacity and discipline-specific performance in combat sports and speed-strength disciplines. Therefore, the study aims to examine the effect of acute, different-dose CAF ingestion on physical capacity and discipline-specific performance in combat sports and speed-strength athletes, in a randomized, double-blind, placebo-controlled crossover trial.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | The Influence of Caffeine Supplementation on Discipline-Specific Performance and Training Activities in Combat Sports and Speed-Strength Disciplines |
Actual Study Start Date : | May 15, 2017 |
Estimated Primary Completion Date : | February 1, 2021 |
Estimated Study Completion Date : | March 1, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Caffeine supplementation
Group taking oral CAF (Caffeine) supplementation in a different-dose crossover regimen.
|
Dietary Supplement: Caffeine supplementation
The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 45 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced. |
Placebo Comparator: Placebo treatment
Group taking oral supplementation with placebo.
|
Dietary Supplement: Placebo treatment
The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 45 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced. |
- Changes in discipline-specific exercise capacity after caffeine supplementation and placebo treatment [ Time Frame: Baseline and during 1 day of acute CAF and PLA supplementation ]Assessment of the discipline-specific exercise capacity tests carried out at baseline, and after CAF and PLA supplementation
- Changes in sports training / competition activities after discipline-specific exercise tests [ Time Frame: Baseline and during 1 day of acute CAF and PLA supplementation ]Assessment of the sports training / competition activities after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation
- Changes in rate of perceived exertion after discipline-specific exercise tests [ Time Frame: Baseline and during 1 day of acute CAF and PLA supplementation ]Assessment of the Borg Rating of Perceived Exertion (RPE) scale after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation
- Changes in heart rate during discipline-specific exercise tests [ Time Frame: Baseline and during 1 day of acute CAF and PLA supplementation ]Assessment of the Heart Rate during and after discipline-specific exercise tests carried out at baseline, and after CAF and PLA supplementation

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- written consent to participate,
- a current medical clearance to practice sports,
- training experience: at least 2 years,
- minimum of 4 workout sessions (in the discipline covered by the study) a week.
Exclusion Criteria:
- current injury,
- any health-related contraindication,
- declared general feeling of being unwell,
- unwilling to follow the study protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03822663
Poland | |
Poznan University of Life Sciences, ul.Wojska Polskiego 31 | |
Poznań, Wielkopolska, Poland, 60-624 |
Principal Investigator: | Krzysztof Durkalec-Michalski, PhD | Poznan University of Life Sciences |
Responsible Party: | Krzysztof Durkalec-Michalski, PhD, Principal Investigator, Poznan University of Life Sciences |
ClinicalTrials.gov Identifier: | NCT03822663 |
Other Study ID Numbers: |
ULS00007 |
First Posted: | January 30, 2019 Key Record Dates |
Last Update Posted: | April 10, 2020 |
Last Verified: | April 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | Shared data will be exclusively related to the level of recorded indicators, without personal data. The data obtained will be attached to scientific publications, depending on the requirements of the journal. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Sports nutrition Caffeine Physical capacity Exercise performance |
Caffeine Central Nervous System Stimulants Physiological Effects of Drugs Phosphodiesterase Inhibitors Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents |